Table 1 Cardiovascular disease treatment strategies involving ferroptosis

BMSCS-EXO

Increases GSH level

Myocardial I/R injury

[88]

FRATAXIN

Reduces mitochondrial iron and ROS level

Myocardial I/R injury

[91]

RESVERATROL

Regulates USP19-Beclin1 autophagy

Myocardial I/R injury

[92]

NARINGIN

Regulates the NRF2 /System xc—/GPX4 pathway

Myocardial I/R injury

[93]

SMI

Activates Nrf2/GPX4 pathway

Myocardial I/R injury

[94]

SSYXC

Increases transferrin level

Atrial fibrillation

[164]

DESFERRIAMINE

Inhibits iron overload

COVID-19-associated cardiomyopathy

[104]

LACTOFERRIN

Inhibits iron overload

COVID-19-associated cardiomyopathy

[107]

MELATONIN

Reduces ACSL4 level and increases GPX4 level

Chemotherapy-related cardiomyopathy

[121]

EMPAGLIFLOZIN

Regulates NLRP3 and myd88 related pathways

Chemotherapy-related cardiomyopathy

[122]

FERROSTATIN-1

Inhibits lipids peroxidation

Hypertrophic cardiomyopathy

[127]

DHA

Increases SLC7A11 level

Hypertrophic cardiomyopathy

[165]

ABCB7

Interacts with mitochondrial complex IV and V

Hypertrophic cardiomyopathy

[134]

PUERARIN

Inhibits iron overload and lipids peroxidation

Hypertrophic cardiomyopathy

[135]

Losartan

Inhibits iron overload

Hypertrophic cardiomyopathy

[136]